Clinical Trial to Evaluate the Use of Platelet Rich Plasma in Front Hyaluronic Acid in Coxarthrosis

PHASE3CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
Coxarthrosis
Interventions
DRUG

Platelet rich plasma

Platelet rich plasma (PRP) is a platelet concentrated obtained from autologous blood centrifugation. This concentration technique provides larger amounts of biologically active molecules, mainly growth factors that are responsible for tissue repair. PRP (platelet rich plasma) contains a higher concentration of platelets from baseline (150,000-350,000 / ul).

DRUG

Hylan G-F 20

Hylan G-F 20 is a viscous, sterile and non-pyrogenic elasto fluid containing hylan. Hylans are byproducts from hyaluronate (hyaluronic acid sodium salt), consisting of repeating disaccharides of N-acetylglucosamine and sodium glucuronate. Hylan G-F 20 replaces and supplements the synovial fluid. It is effective at any stage of the joint pathology.

Trial Locations (2)

36002

Complejo Hospitalario de Pontevedra, Pontevedra

41009

Hospital Universitario Virgen Macarena, Seville

All Listed Sponsors
lead

Fundación Pública Andaluza Progreso y Salud

OTHER

NCT02694146 - Clinical Trial to Evaluate the Use of Platelet Rich Plasma in Front Hyaluronic Acid in Coxarthrosis | Biotech Hunter | Biotech Hunter